CN106727733B - Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof - Google Patents
Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof Download PDFInfo
- Publication number
- CN106727733B CN106727733B CN201611222091.9A CN201611222091A CN106727733B CN 106727733 B CN106727733 B CN 106727733B CN 201611222091 A CN201611222091 A CN 201611222091A CN 106727733 B CN106727733 B CN 106727733B
- Authority
- CN
- China
- Prior art keywords
- cordyceps sinensis
- fresh cordyceps
- extract
- fresh
- cisplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 73
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 50
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 48
- 229960004316 cisplatin Drugs 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 238000000605 extraction Methods 0.000 claims abstract description 23
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 15
- 201000005202 lung cancer Diseases 0.000 claims abstract description 15
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 14
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 6
- 210000005084 renal tissue Anatomy 0.000 claims abstract description 6
- 239000006228 supernatant Substances 0.000 claims description 19
- 238000007710 freezing Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000010008 shearing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000190633 Cordyceps Species 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 8
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000000451 tissue damage Effects 0.000 abstract description 5
- 231100000827 tissue damage Toxicity 0.000 abstract description 5
- 238000009098 adjuvant therapy Methods 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 230000001276 controlling effect Effects 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 101000578412 Amyda cartilaginea Lysozyme C Proteins 0.000 description 3
- 102100027710 Astacin-like metalloendopeptidase Human genes 0.000 description 3
- 101000936739 Homo sapiens Astacin-like metalloendopeptidase Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010048899 Radiation oesophagitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a combined medicine for cordyceps antitumor chemotherapy, which comprises a fresh cordyceps extract and cisplatin, wherein the fresh cordyceps extract is obtained by taking fresh cordyceps as a raw material and water as an extraction solvent and adopting flash extraction and ultrafiltration. More particularly, the cordyceps sinensis extract has the effects of reducing toxicity and enhancing the efficiency of adjuvant therapy of tumor chemotherapy, can enhance the inhibiting effect of chemotherapeutic drugs on the growth of lung cancer cells, and has the protective effect on liver and kidney tissue damage caused by the chemotherapeutic drugs. The fresh cordyceps sinensis extract provided by the invention has obvious attenuation synergistic effect on adjuvant therapy of tumor chemotherapy, has a protective effect on liver and kidney tissue damage caused by chemotherapy drugs for the first time, and provides scientific basis and important information for further research of new application and research of drug action mechanism.
Description
Technical Field
The invention relates to the field of drug combination application, in particular to a combination drug of fresh cordyceps sinensis for anti-tumor chemotherapy and application thereof.
Background
Malignant tumor is one of the main diseases which endanger human survival and health at present, and the treatment means mainly comprise surgery, chemotherapy and radiotherapy. Among them, the surgical treatment is limited by the development degree of the disease, the constitution of the patient, the existence of other diseases and other conditions, and the tumor is removed by physical means such as surgery, which can only treat the symptoms but not the root cause. Radiotherapy, which is an important means for treating malignant tumors, can produce good effects, but can produce radiodermatitis, radiation esophagitis, appetite decrease, nausea, vomiting, abdominal pain, diarrhea, immunity decrease and other toxic and side effects. Chemotherapy is one of the more effective and commonly used methods in the comprehensive treatment of malignant tumors at present, but single chemotherapy often causes immunosuppression and other adverse reactions and toxic and side effects, which lead to repeated malignant infection and poor prognosis and accelerate death of patients and other adverse reactions. For example, cisplatin chemotherapeutic drugs as the first generation antitumor platinum drugs have very good therapeutic effects on reproductive system cancer, head and neck cancer, osteosarcoma and the like, account for 70% -80% of the drugs for treating malignant tumors in clinical chemotherapy or combined chemotherapy, and also have a certain effect on the clinical treatment of solid tumors such as lung cancer, gastric cancer, mesothelioma and the like, but the single use of cisplatin drugs can cause certain side effects such as severe gastrointestinal reactions, nephrotoxicity, ototoxicity and neurotoxicity, and the long-term single use can cause increasingly severe drug resistance. Therefore, the research and development of the natural traditional Chinese medicine which has high efficiency, low toxicity and easy popularization and can be used for chemotherapy with double functions of synergism and attenuation becomes a problem to be solved urgently in clinic.
The Cordyceps sinensis is a complex of a stroma and a larva body parasitic on a larva of a hepialidae insect in the Clavicipitaceae fungus Cordyceps sinensis (Berk.) Sacc, is a special and precious Chinese traditional medicine, contains various active ingredients such as nucleoside, polysaccharide, protein, amino acid and the like, and has the effects of tonifying lung and kidney, stopping bleeding and reducing phlegm and the like in the traditional Chinese medicine. A large number of researches show that the cordyceps sinensis has the capabilities of resisting fatigue and anoxia and resisting viruses, has a certain regulating effect on liver, lung, kidney, cardiovascular, immunity, nerves and the like, and has an inhibiting effect on the proliferation of various tumor cells such as melanoma, gastric cancer, lung cancer, thyroid cancer, breast cancer and the like. However, in the existing literature reports, cordyceps sinensis is dried in the shade, dried or dried in the sun, or cordyceps sinensis mycelium fermentation liquor, cordyceps flower and the like are used as research materials, and extracts are mostly obtained by boiling, high-temperature ultrasonic or reflux extraction, and the treatment methods may cause the structural change of partial active substances, so that the pharmacological activity of cordyceps sinensis is affected. At present, there are few reports related to the lung tumor resistance of cordyceps sinensis combined with chemical drugs. For example, as described in the literature, "experimental study on tumor inhibition effect of cordyceps sinensis decoction in combination with cisplatin on tumor-bearing mice", the cordyceps sinensis decoction is obtained by high-temperature heating and decocting in a conventional method, and the tumor inhibition effect on the tumor-bearing mice with HCTB (colorectal cancer) is studied by combining with cisplatin, the result shows that the cordyceps sinensis decoction in combination with cisplatin can reduce the tumor mass of the mice inoculated with HCTB, but the cordyceps sinensis is not mentioned to reduce the toxicity effect of cisplatin. According to the report of the clinical observation of the cordyceps sinensis combined NP scheme for treating the advanced non-small cell lung cancer, cordyceps sinensis particles (provided by the research department of Central research institute of Xiaolin pharmaceutical (strain) of Japan, and the cordyceps sinensis fermentation mycelium is supposed to be) are combined with a plurality of chemotherapeutic drugs including vinorelbine and cisplatin in the NP scheme for treating the advanced non-small cell lung cancer, the cost of the combined use of the plurality of chemotherapeutic drugs is high, the cordyceps sinensis fermentation product is used, active substances are not clear, the effective rate and the benefit rate of a treatment group are only found to be 35.5% and 58.8%, the change of the Kaschin score of the quality of life of the treatment group is only slightly higher than that of a control group which only takes the chemotherapeutic drugs and does not take the cordyceps sinensis particles, the change of the Kaschin score of the quality of the treatment group is not very large, and in addition, certain toxic and side.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a combined drug of fresh cordyceps sinensis and anti-tumor chemotherapy and application thereof. The fresh cordyceps sinensis provided by the invention is not subjected to sun-drying and drying treatment, and an efficient extraction method is provided. The fresh cordyceps sinensis extract in the anti-tumor chemotherapy combined medicine has a synergistic effect when being combined with cisplatin, has a protective effect on liver and kidney tissue damage caused by tumor chemotherapy, and has a good development prospect.
The purpose of the invention is realized by the following technical scheme:
on one hand, the invention provides a cordyceps combined medicine for anti-tumor chemotherapy, which comprises a fresh cordyceps extract and cisplatin, wherein the fresh cordyceps extract is obtained by taking fresh cordyceps as a raw material and water as an extraction solvent and adopting flash extraction and ultrafiltration.
In some embodiments, the fresh cordyceps extract is obtained by using freshly harvested cordyceps as a raw material, using water as an extraction solvent, controlling the temperature at 20-25 ℃, performing flash extraction, then performing centrifugation, collecting supernatant, performing ultrafiltration, and performing freeze-drying treatment.
In some embodiments, the method for preparing the fresh cordyceps sinensis extract comprises the following steps:
a. cutting fresh cordyceps sinensis into pieces, adding water with the weight volume ratio of 1: 10-12 g/mL into the fresh cordyceps sinensis and the water, soaking for 3-5 h, and controlling the temperature to be 20-25 ℃;
b. extracting the soaked fresh cordyceps sinensis in a flash extractor, centrifuging, collecting supernatant, and controlling the temperature to be 20-25 ℃;
c. adding water into the centrifuged precipitate, freezing, rapidly freezing and thawing, repeating the step b, performing flash extraction, centrifuging, and collecting supernatant;
d. combining the supernatants collected in the step b and the step c, adding water for dilution, filtering, and then carrying out ultrafiltration;
e. and (4) freeze-drying the ultrafiltered retention solution to obtain the fresh cordyceps sinensis extract.
In some embodiments, wherein in step b, the flash extraction conditions are: performing flash extraction for 2 times, wherein the extraction time is 80-120 s each time, the rotating speed is 8000-10000 rpm, and the voltage is 120-160V; the centrifugation conditions are as follows: the centrifugation time is 15min, and the centrifugation rotating speed is 10000 rpm-12000 rpm.
In some embodiments, in step c, the weight-to-volume ratio of the precipitation water to the dilution water is 1: 10-12 g/mL; the freezing temperature is-20 ℃, and the freezing time is 4 h.
In some embodiments, wherein in step d, the volume ratio of the supernatant to water is 1: 4; the filtering medium is a 0.45 mu m micro-membrane; the ultrafiltration conditions are as follows: using ultrafiltration membrane with cut-off molecular weight more than 5KDa, setting temperature at 25 deg.C, time at 15min, and pressure at 0.08 KPa.
In some embodiments, the method for preparing the fresh cordyceps sinensis extract comprises the following steps:
a. cleaning and draining fresh cordyceps sinensis, shearing the cordyceps sinensis to be within 0.2cm in length, adding water with the weight volume ratio of 1: 10-1: 12 into the cordyceps sinensis and water, soaking for 3-5 h, and controlling the temperature to be 20-25 ℃;
b. placing the soaked fresh cordyceps sinensis in a flash extractor, carrying out flash extraction for 2 times, wherein the extraction time is 80-120 s each time, the rotating speed is 8000-10000 rpm, the voltage is 120-160V, then centrifuging for 15min, the rotating speed of centrifuging is 10000-12000 rpm, taking supernatant, and controlling the temperature to be 20-25 ℃;
c. adding water in a weight-volume ratio of 1: 10-1: 12 into the centrifuged precipitate, freezing for 4 hours in an environment at the temperature of-20 ℃, quickly freezing and thawing, repeating the step b, performing flash extraction, centrifuging, and collecting supernatant;
d. combining the supernatants collected in the steps b and c, adding water to dilute by 4 times, filtering by using a 0.45-micron micro-membrane, and then performing ultrafiltration by using an ultrafiltration membrane with a cut-off molecular weight of more than 5KDa at a set temperature of 25 ℃, for 15min and under a pressure of 0.08 KPa;
e. and (4) freeze-drying the ultrafiltered retention solution to obtain the fresh cordyceps sinensis extract.
On the other hand, the invention provides an application of the combined medicine in preparing tumor chemotherapy medicines.
In some embodiments, wherein the tumor chemotherapeutic has an inhibitory effect on lung cancer Lewis cells.
In some embodiments, wherein the tumor chemotherapeutic agent has a protective effect on liver and kidney tissue damage caused by tumor chemotherapy.
The combination of the present invention is not limited to the state in which it is finally administered to a patient, and may be in the form of an oral liquid, a capsule, a tablet, or the like.
The invention has the following positive effects:
1. the research on the pharmacological activity of the fresh cordyceps sinensis is still in the blank field, and the invention adopts a flash extractor to extract macromolecular chemical components in the fresh cordyceps sinensis under the condition of controlling low temperature, thereby well playing the medicinal effect.
2. The invention discovers that the combined application of the fresh cordyceps sinensis cold water extract and the cisplatin has remarkable synergy and attenuation effects on lung tumor chemotherapy for the first time.
3. The invention discovers that the combination of the fresh cordyceps sinensis cold water extract and cisplatin has a protective effect on liver and kidney tissue damage caused by tumor chemotherapy for the first time.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Fresh cordyceps sources: collected fresh by Yichang Shancheng Shuihu Cordyceps Gmbycis.
Ultrasonic instrument sources and parameters: KQ-500DB digital control ultrasonic cleaning machine (kunshan ultrasonic instrument limited), power: 500W; ultrasonic frequency: 40 KHz.
The centrifugal equipment is sourced from: 272R-3 ultra-large capacity refrigerated centrifuge (Hunan Xiangli instrumentation factory)
First, preparation example
Example 1
Taking 10g of fresh cordyceps sinensis, cleaning, cutting into pieces with the length of 0.2cm, adding 100mL of deionized water, soaking for 3h, and controlling the temperature at 20-25 ℃. Placing the soaked fresh Cordyceps in a flash extractor, controlling the temperature at 20-25 deg.C, voltage at 120V, rotation speed at 8000rpm, and time at 80 s. Centrifuging at 10000rpm for 15min, and collecting supernatant. Freezing the residue at-20 deg.C for 4 hr, and rapidly freezing and thawing. Then 100mL of deionized water was added, and the mixture was placed in a flash extractor for extraction, centrifuged, and the supernatant was collected. The supernatants from both were combined. Diluting the supernatant with deionized water 4 times, filtering with 0.45 μm microfilm, ultrafiltering with ultrafiltration membrane to cut off components with molecular weight greater than 5KDa, setting temperature at 25 deg.C, time at 15min, and pressure at 0.08 KPa. And finally, freeze-drying the retention solution after ultrafiltration to obtain 1.62g of the fresh cordyceps sinensis extract with the extraction rate of 16.2%.
Example 2
Taking 10g of fresh cordyceps sinensis, cleaning, cutting into pieces with the length of 0.2cm, adding 120mL of deionized water, soaking for 5h, and controlling the temperature at 20-25 ℃. Placing the soaked fresh Cordyceps in a flash extractor, controlling the temperature at 20-25 deg.C, the voltage at 160V, the rotation speed at 10000rpm, and the time at 120 s. Centrifuging at 12000rpm for 15min, and collecting supernatant. Freezing the residue at-20 deg.C for 4 hr, and rapidly freezing and thawing. Then 120mL of deionized water was added and the mixture was placed in a flash extractor for extraction, centrifuged, and the supernatant was collected. The supernatants from both were combined. Diluting the supernatant with deionized water 4 times, filtering with 0.45 μm microfilm, ultrafiltering with ultrafiltration membrane to cut off components with molecular weight greater than 5KDa, setting temperature at 25 deg.C, time at 15min, and pressure at 0.08 KPa. And finally, freeze-drying the retention solution after ultrafiltration to obtain 1.55g of the fresh cordyceps sinensis extract with the extraction rate of 15.5%.
Example 3
Taking 10g of fresh cordyceps sinensis, cleaning, shearing into pieces with the length of 0.2cm, freeze-drying, controlling the temperature to be 20-25 ℃ for superfine grinding, adding 100mL of deionized water, extracting in 90 ℃ water bath for 1.5h, and filtering. Extracting the residue with 100mL deionized water in 90 deg.C water bath, filtering, and mixing the extractive solutions. Filtering with 0.45 μm microfilm, keeping filtrate, and freeze drying to obtain fresh Cordyceps extract 1.60g with extraction rate of 16.0%.
Second, test example
Experiment 1, application of fresh Cordyceps extract in research of antitumor, toxicity reducing and synergistic effects
1. Experimental Material
The experimental animals were from SPF grade C57BL/6 female mice from Schlay, Hunan, and ranged in weight from 18g to 20 g. After purchase, the animals are observed in a quarantine room for one week and then transferred to an SPF laboratory for breeding.
The cold extract of fresh cordyceps sinensis in example 1 and the hot extract of fresh cordyceps sinensis in example 3 are dissolved in deionized water to prepare drug concentrations of 20mg/mL and 80mg/mL respectively. The cordyceps sinensis extract is administrated by intragastric administration, the intragastric volume of a mouse is 10mL/kg, and the administration is carried out once a day according to the low dose of 200mg/kg and the high dose of 800 mg/kg; cisplatin is administrated by intraperitoneal injection, the volume of the intraperitoneal injection is 1mL/kg, the administration dose is 2mg/kg, and the cisplatin is administrated every other day.
2. Design of experiments
(1) Cell culture
Culturing mouse Lewis lung cancer cells in DMEM medium containing 10% fresh fetal calf serum at 37 deg.C with volume fraction of 5% CO2And continuously culturing in an incubator with saturated humidity. Until logarithmic phase, the cells were adjusted to 1X 10 by conventional digestion with 0.25% pancreatin6Suspension per mL.
(2) Establishment and administration of animal grouping and lung cancer mouse model
The animal weight was randomly divided into A, B, C, D, E, F groups of 6 groups, representing model group, cis-platinum group (2mg/kg), cis-platinum (2mg/kg), fresh Cordyceps hot extract low dose group (200mg/kg), cis-platinum (2mg/kg), fresh Cordyceps hot extract high dose group (800mg/kg), cis-platinum (2mg/kg), fresh Cordyceps cold extract low dose group (200mg/kg), cis-platinum (2mg/kg) and fresh Cordyceps cold extract high dose group (800mg/kg), and each group had 15 animals, for a total of 90 animals.
7 days before the experiment, C, D, E, F groups of mice were gavaged daily with fresh Cordyceps extract at the corresponding dose, and A and B groups were gavaged daily with deionized water at the same amount. On day 8, A, B, C, D, E, F6 mice were inoculated subcutaneously with Lewis lung carcinoma cells 1X 10 in the axilla of the left limb6At the same time, C, D, E, F groups of mice were gavaged with fresh Cordyceps extract at the corresponding dose, and A, B groups of mice were gavaged with deionized water at the same amount. After day 9, mice in group B were injected intraperitoneally with 2mg/kg cisplatin solution, and administered every other day; group C mice: preparing 200mg/kg fresh Cordyceps hot extract, and intragastric administrationContinuously for 20 days, preparing 2mg/kg cis-platinum solution for intraperitoneal injection at the same time, and administering every other day; group D mice: preparing 800mg/kg fresh Cordyceps hot extract, performing intragastric administration for 20 days, and preparing 2mg/kg cisplatin solution for intraperitoneal injection, and performing administration every other day; group E mice: preparing 200mg/kg of fresh Cordyceps sinensis cold extract, performing intragastric administration for 20 days continuously, and simultaneously preparing 2mg/kg of cisplatin solution, performing intraperitoneal injection, and performing administration every other day; group F mice: preparing 800mg/kg of fresh Cordyceps sinensis cold extract, performing intragastric administration for 20 days continuously, and simultaneously preparing 2mg/kg of cisplatin solution, performing intraperitoneal injection, and performing administration every other day; group a mice were gavaged daily with an equal amount of saline.
After 24h of administration on day 28, the mice were weighed, then the eyeballs were removed and blood was collected, after standing for 4h, the serum was separated by centrifugation, and glutamate-oxaloacetate transaminase (ASTL), glutamate-pyruvate transaminase (ALTL), urea nitrogen (UREAL), and serum creatinine (CREA2) were measured according to the procedure of the ELISA kit. And (3) removing cervical vertebrae, killing the mice, stripping tumor masses, weighing tumor mass and organ mass, and calculating tumor inhibition rate and organ coefficient. Wherein, the tumor inhibition rate calculation formula is as follows: tumor inhibition rate/% (average tumor mass of control group-average tumor mass of administration group)/average tumor mass of control group × 100%, organ coefficient calculation formula is:
all experimental data were normalized, statistically analyzed using SPSS16, single-factor analysis of variance was performed, and p-values were calculated.
3. Results
(1) Synergistic results
The influence of the fresh cordyceps sinensis extract on the growth of Lewis lung cancer cells and the synergistic effect on cisplatin are shown in Table 1:
TABLE 1 Effect of fresh Cordyceps extract on Lewis lung carcinoma cell growth and cisplatin synergism
| Group of | Dosage/mg. kg-1 | Tumor weight (g) | Tumor inhibition Rate (%) |
| A. Model administration set | - | 3.27±0.42** | - |
| B. Cisplatin administration group | 2 | 1.77±0.22 | 45.9 |
| (example 3+ cisplatin) administration group | 200+2 | 2.09±0.43 | 36.1 |
| (example 3+ cisplatin) administration group | 800+2 | 1.58±0.26 | 45.7 |
| EXAMPLE 1 cisplatin administration group | 200+2 | 1.19±0.20* | 63.6 |
| (example 1+ cisplatin) administration group | 800+2 | 1.08±0.28* | 67.0 |
Note: compared to the cisplatin group: p is less than 0.05,**p is less than 0.01; "-" indicates none.
As can be seen from the data in table 1, the example 1 (cold extract of fresh cordyceps sinensis) combined cisplatin administration group can reduce the weight of the tumor and show significant difference (p < 0.05) compared with cisplatin administration group, and the tumor inhibition rate is as high as 67%, which indicates that the cold extract of fresh cordyceps sinensis can enhance the curative effect of cisplatin and has statistical difference compared with cisplatin group. However, in example 3 (fresh cordyceps sinensis heat extract) combined with cisplatin administration, compared with cisplatin group, the tumor quality is not reduced, and the tumor inhibition rate is reduced to a certain extent, which indicates that the tumor weight of the lung cancer mice cannot be reduced by combining fresh cordyceps sinensis heat extract with cisplatin administration, compared with cisplatin group, and the fresh cordyceps sinensis heat extract does not achieve synergistic effect on adjuvant therapy of tumor chemotherapy.
(2) Attenuation results
The effect of the administration of fresh cordyceps sinensis in combination with cisplatin on the organ coefficients of lung cancer mice is shown in table 2:
TABLE 2 Effect of fresh Cordyceps combined with cisplatin administration on organ coefficients of mice with lung cancer
Note: compared to the cisplatin group: p is less than 0.05,**p is less than 0.01; "-" indicates none.
As can be seen from Table 2, the combination of example 1 (cold extract of fresh Cordyceps sinensis) and cisplatin can significantly improve the atrophy of organs of mice with lung cancer caused by cisplatin, wherein the attenuation effect of example 1 (cold extract of fresh Cordyceps sinensis) is more significant than that of example 3 (hot extract of fresh Cordyceps sinensis), especially the spleen and thymus. The cold extract of fresh cordyceps sinensis can resist the immunosuppression caused by the chemotherapeutic drug cisplatin, promote the recovery of the immunologic function of the organism and further improve the anti-tumor effect of the organism.
(3) Biochemical index measurement result
The influence of the administration of fresh cordyceps sinensis and cisplatin on the biochemical indexes of the lung cancer mice is shown in table 3:
TABLE 3 Effect of fresh Cordyceps combined with cisplatin on Biochemical index of mice with lung cancer
Note: compared to the cisplatin group: p < 0.05, p < 0.01;
as can be seen from the data in table 3, compared with the cisplatin administration group, when the fresh cordyceps sinensis cold extract and the combined cisplatin are administered in example 1, the contents of ASTL, ALTL, UREAL and CREA2 are significantly reduced (ALTL, UREAL and CREA2 are p < 0.05), which indicates that the fresh cordyceps sinensis extract and the cisplatin combined can protect liver and kidney injury caused by the antitumor active drug; in the case of the group of the fresh cordyceps sinensis heat extract and the cisplatin administration in example 3, the contents of ASTL, ALTL, UREAL and CREA2 have no significant difference, which indicates that the fresh cordyceps sinensis heat extract has a non-obvious effect on protecting liver and kidney injury caused by the antitumor active drug.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention. All publications or patents cited herein are incorporated by reference.
Claims (3)
1. A pharmaceutical composition of Cordyceps sinensis for resisting Lewis lung cancer comprises fresh Cordyceps sinensis extract and cisplatin, wherein the preparation method of the fresh Cordyceps sinensis extract comprises the following steps:
a. cleaning and draining fresh cordyceps sinensis, shearing the cordyceps sinensis to be within 0.2cm in length, adding water with the weight volume ratio of 1: 10-1: 12 into the cordyceps sinensis and water, soaking for 3-5 h, and controlling the temperature to be 20-25 ℃;
b. placing the soaked fresh cordyceps sinensis in a flash extractor, carrying out flash extraction for 2 times, wherein the extraction time is 80-120 s each time, the rotating speed is 8000-10000 rpm, the voltage is 120-160V, then centrifuging for 15min, the rotating speed of centrifuging is 10000-12000 rpm, taking supernatant, and controlling the temperature to be 20-25 ℃;
c. adding water in a weight-volume ratio of 1: 10-1: 12 into the centrifuged precipitate, freezing for 4 hours in an environment at the temperature of-20 ℃, quickly freezing and thawing, repeating the step b, performing flash extraction, centrifuging, and collecting supernatant;
d. combining the supernatants collected in the steps b and c, adding water to dilute by 4 times, filtering by using a 0.45-micron micro-membrane, and then performing ultrafiltration by using an ultrafiltration membrane with a cut-off molecular weight of more than 5KDa at a set temperature of 25 ℃, for 15min and under a pressure of 0.08 KPa;
e. and (4) freeze-drying the ultrafiltered retention solution to obtain the fresh cordyceps sinensis extract.
2. Use of the pharmaceutical composition of claim 1 in the preparation of a medicament for treating Lewis lung cancer.
3. The use according to claim 2, wherein the pharmaceutical composition is effective in protecting liver and kidney tissue from damage caused by tumor chemotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611222091.9A CN106727733B (en) | 2016-12-27 | 2016-12-27 | Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611222091.9A CN106727733B (en) | 2016-12-27 | 2016-12-27 | Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106727733A CN106727733A (en) | 2017-05-31 |
| CN106727733B true CN106727733B (en) | 2020-03-24 |
Family
ID=58925842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611222091.9A Active CN106727733B (en) | 2016-12-27 | 2016-12-27 | Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727733B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526127A (en) * | 2012-03-28 | 2012-07-04 | 辽宁大学 | Flash type extraction method for active constituents in cordyceps militaris |
| CN103214533A (en) * | 2013-04-19 | 2013-07-24 | 湖南农业大学 | Method for continuously preparing cordycepin and cordyceps polysaccharide by using membrane separation technology |
-
2016
- 2016-12-27 CN CN201611222091.9A patent/CN106727733B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526127A (en) * | 2012-03-28 | 2012-07-04 | 辽宁大学 | Flash type extraction method for active constituents in cordyceps militaris |
| CN103214533A (en) * | 2013-04-19 | 2013-07-24 | 湖南农业大学 | Method for continuously preparing cordycepin and cordyceps polysaccharide by using membrane separation technology |
Non-Patent Citations (1)
| Title |
|---|
| 冬虫夏草合用顺铂诱导非小细胞肺癌凋亡的研究;徐晋等;《南京中医药大学学报》;20081130;第24卷(第06期);第398-400页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106727733A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| TW201618801A (en) | Pharmaceutical composition used for assisting chemotherapy drug and application thereof | |
| WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
| CN101249259A (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN106727733B (en) | Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN108553504A (en) | Join stilbene powder and preparation method thereof | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN108939043A (en) | A kind of Shark cartilage glycoprotein and its anticancer purpose | |
| CN104825783B (en) | Chinese medicine composition with antitumor activity and its preparation method and application | |
| CN110279780B (en) | Traditional Chinese medicine solution capable of inhibiting growth of tumor cells | |
| CN113134034A (en) | Traditional Chinese medicine composition, application and traditional Chinese medicine preparation | |
| TW201808316A (en) | Use of compositions of water/alcohol extracts of Antrodia cinnamomea cut-log cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN106110312A (en) | Ulinastatin purposes in preparation treatment carcinoma of gallbladder medicine | |
| CN108635560A (en) | A kind of Chinese medicine and preparation method thereof for treating lymthoma | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN110025643B (en) | Compound with anticancer activity and preparation method and application thereof | |
| CN109223819A (en) | Hundred tail gracilis polysaccharides are for the purposes in immunological regulation and anti-tumor drug | |
| CN111298061B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof | |
| CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1234653 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200525 Address after: Room 302, building 32, No. 368, Zhenan Middle Road, Chang'an Town, Dongguan City, Guangdong Province Co-patentee after: YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Patentee after: Dongguan dongyangguang Cordyceps research and Development Co.,Ltd. Address before: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1 Co-patentee before: YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A combined drug of fresh Cordyceps sinensis for anti-tumor chemotherapy and its application Effective date of registration: 20210923 Granted publication date: 20200324 Pledgee: Shenzhen branch of China Import and Export Bank Pledgor: Dongguan dongyangguang Cordyceps research and Development Co.,Ltd.|YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Registration number: Y2021980009771 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220926 Granted publication date: 20200324 Pledgee: Shenzhen branch of China Import and Export Bank Pledgor: Dongguan dongyangguang Cordyceps research and Development Co.,Ltd.|YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Registration number: Y2021980009771 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A combination of fresh Cordyceps sinensis with anti-tumor chemotherapy and its application Effective date of registration: 20220929 Granted publication date: 20200324 Pledgee: Shenzhen branch of China Import and Export Bank Pledgor: Dongguan dongyangguang Cordyceps research and Development Co.,Ltd.|YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Registration number: Y2022980017022 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230920 Granted publication date: 20200324 Pledgee: Shenzhen branch of China Import and Export Bank Pledgor: YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd.|Dongguan dongyangguang Cordyceps research and Development Co.,Ltd. Registration number: Y2022980017022 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A combination drug of fresh Cordyceps sinensis for anti-tumor chemotherapy and its application Effective date of registration: 20230927 Granted publication date: 20200324 Pledgee: Shenzhen branch of China Import and Export Bank Pledgor: Dongguan dongyangguang Cordyceps research and Development Co.,Ltd.|YICHANG SHANCHENGSHUIDU CORDYCEPS Co.,Ltd. Registration number: Y2023980059372 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |